September 9, 2022 7:42am
Issues = volatility and resistance, although stock futures point to gains
Indications: 2 Positive Indications and 1 Pump/Promote
RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
More frequently right than consequentially wrong; there is VALUE out there. What I provide is an intelligence daily.
The 8:00 A.M., ET edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.72% or (+221 points), S&P futures are UP +0.75% (+30 points) and NASDAQ futures are UP +0.97% (+120 points) early in the pre-open – so far,
U.S. stock futures rose Friday,
European markets were higher,
Asia Pacific markets higher.
Henry’omics:
Thursday’s rally had an up-and-down session, selling off near the open, rebounding for solid gains, and going back and forth before finally advancing with decent gains after Wednesday's strong rebound.
Last night, “The Dow closed UP +193.24 points (+0.61); the S&P closed UP +26.31 points (+0.66%) while the Nasdaq closed UP +70.23 points (+0.60%)”.
Those gains put all three major averages on pace to snap a 3-week losing streak. Through Thursday, the Dow is up 1.45%. Meanwhile, the S&P 500 is up 2.09%, and the Nasdaq is 1.99% higher.
To be closely watched: the bond-market gauge of near-term inflation expectations has fallen below the Fed's 2% target for the first time in two years.
RegMed Investors’ (RMi) closing bell: “hang-on to the overbought upside, it’s a hot plate – gloves needed; the cool-off is coming in a nervous market in a pre-CPI week. Hedge funds are nervous re the alternating share pricing dives and jives.” … https://www.regmedinvestors.com/articles/12595
Ebb and flow –
Q3/22 – September – 1 holiday, 3 positive and 2 negative closes
· August – 1 neutral, 11 positive and 11 negative closes
· July - 1 holiday, 10 negative and 10 positive closes
Q2/22 –
· June – 1 holiday, 9 positive and 11 negative closes
· May - 11 positive and 10 negative closes
· April - 1 holiday, 6 positive and 13 negative closes
Q1/22:
· March – 13 negative and 10 positive closes
· February stats: 11 negative, 8 positive closes and 1 holiday
· January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
Positive Indications:
uniQure NV (QURE) closed up +$1.35 to $20.85 after Tuesday’s -$1.116 after Monday’s holiday following Friday’s $20.66 and Thursday’s $20.67 with a positive +$0.60 or +2.78% pre-open indication,
Beam Therapeutics (BEAM) closed up +$1.26to $57.07 after Wednesday’s +$2.88 and Tuesday’s +$0.25 with a positive +$0.23 or +0.40%% pre-open indication.
Puff/Pump and Promote: Maintaining SELL
Biostage (OTCQB: BSTG) closed up +$0.59 with 3,872 shares traded after Wednesday’s -$0.60, Tuesday’s $0.00 with 34 shares traded, Monday’s holiday following Friday’s $0.00 Thursday’s $0.00 and last Wednesday’s $0.00 <3-month average = 1,619>,
· How much lipstick is a lot on this pig with an almost 4-year-old IND and NO clinical trial initiation?
· WATCH and be ready for a BIG reverse of shares to enable offering from multiple private placements as it tries to facilitate an offering with Newbridge Securities?
The BOTTOM LINE: I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
I try to keep it simple … and short as I love my coverage list – yet, the truth will set investors free from electronic and algorithm control!
September started with 1 holiday, 2 positive and 2 negative closes; August is over with 1 neutral, 11 positive and 11 negative closes while last week which ended the month.
As I continually question, “The real question that should be asked is how many companies are at the end of sentiments … leash? Start by looking at cell and gene therapy companies trading below cash!”
Second Question, “How many companies are LOSING the investment high ground? TOO MANY” …!!!
Investors need to come to terms of the cell and gene therapy sector’s state of affairs and health as individual company’s actions cast doubts upon sentiment as reflected by August’s final accounting of positive and negative closes.
Companies NEED BETTER outreach to investors which means … NOT to enrich themselves at shareholder’s expense!
CEO salaries, spending the G&A are totally OUT-OF-WHACK; these are companies are in the development stage and will be for years without products in most cases not like the tech companies, who CEOs and management teams think they should be compared to for bi-weekly cash and “beanies”!
When it comes time to invest or even hold onto an investment; I’d say … focus on what percentage ownership of stock … NOT options CEOs and management teams own versus their salary and bonus.
Also, investors can’t afford the outsized valuation price targets by I-Banks research and believe that CEOs are “accomplices” to over-estimating expectation and guidance in regard to valuation
The only thing investors are able to hang to at that point is HOPE – which is not a technical or fundamental indicator. Keep your eyes on historical pricings that, haven’t responded to I-Bank research price targets.
As I have written, “I devote a lot of time to the direction of the sector to reckon the geography of my coverage group.”
That doesn't mean you should flee entirely to cash, but investors make sure gains don't evaporate thus … be quick to drop losing positions.
Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
